Farngren J, et al. - In a single-centre, double-blind, randomized, placebo-controlled crossover study, experts aspired to explore whether DPP-4 (dipeptidyl peptidase-4) inhibition affects the glucagon response to hypoglycaemia in the subjects with type 2 diabetes. They discovered that elderly subjects with metformin-treated type 2 diabetes had lower glucagon levels at 3.5 mmol/L glucose, but maintain the glucagon response to hypoglycaemia at 3.1 mmol/L during DPP-4 inhibition, which safeguards against hypoglycaemia and could contribute to minimizing the risk of hypoglycaemia by DPP-4 inhibition in this age group.